Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Updates in therapy for uterine serous carcinoma.

Roque DM, Santin AD.

Curr Opin Obstet Gynecol. 2013 Feb;25(1):29-37. doi: 10.1097/GCO.0b013e32835af98d. Review.

PMID:
23138439
2.

Early stage uterine serous carcinoma: management updates and genomic advances.

Fader AN, Santin AD, Gehrig PA.

Gynecol Oncol. 2013 Apr;129(1):244-50. doi: 10.1016/j.ygyno.2013.01.004. Epub 2013 Jan 12. Review.

PMID:
23321062
3.

Molecular alterations in uterine serous carcinoma.

Hayes MP, Ellenson LH.

Gynecol Oncol. 2010 Feb;116(2):286-9. doi: 10.1016/j.ygyno.2009.11.012. Review.

PMID:
20109727
4.

Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer.

Black JD, English DP, Roque DM, Santin AD.

Womens Health (Lond). 2014 Jan;10(1):45-57. doi: 10.2217/whe.13.72. Review.

5.

Frequent CCNE1 amplification in endometrial intraepithelial carcinoma and uterine serous carcinoma.

Kuhn E, Bahadirli-Talbott A, Shih IeM.

Mod Pathol. 2014 Jul;27(7):1014-9. doi: 10.1038/modpathol.2013.209. Epub 2013 Dec 6.

6.

Adjuvant therapy for patients with stage I papillary serous endometrial cancer.

Alobaid A, Bruchim I, Verkooijen H, Gauthier P, Petignat P.

Eur J Surg Oncol. 2006 Apr;32(3):358-62. Epub 2006 Jan 18. Review.

PMID:
16414233
8.

The management of serous papillary uterine cancer.

Schwartz PE.

Curr Opin Oncol. 2006 Sep;18(5):494-9. Review.

PMID:
16894299
9.

HER2/neu in Endometrial Cancer: A Promising Therapeutic Target With Diagnostic Challenges.

Buza N, Roque DM, Santin AD.

Arch Pathol Lab Med. 2014 Mar;138(3):343-50. doi: 10.5858/arpa.2012-0416-RA. Review.

PMID:
24576030
10.

Mutation of PPP2R1A: a new clue in unveiling the pathogenesis of uterine serous carcinoma.

Shih IeM, Wang TL.

J Pathol. 2011 May;224(1):1-4. doi: 10.1002/path.2884. Epub 2011 Mar 22.

PMID:
21432855
11.

Novel targeted therapies in uterine serous carcinoma, an aggressive variant of endometrial cancer.

Menderes G, Clark M, Santin AD.

Discov Med. 2016 Apr;21(116):293-303.

12.

Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer.

Santin AD, Bellone S, Siegel ER, Palmieri M, Thomas M, Cannon MJ, Kay HH, Roman JJ, Burnett A, Pecorelli S.

Am J Obstet Gynecol. 2005 Mar;192(3):813-8.

PMID:
15746676
13.
14.

Gynecologic Cancer InterGroup (GCIG) consensus review for uterine serous carcinoma.

Sagae S, Susumu N, Viswanathan AN, Aoki D, Backes FJ, Provencher DM, Vaughan M, Creutzberg CL, Kurzeder C, Kristensen G, Lee C, Kurtz JE, Glasspool RM, Small W Jr.

Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S83-9. doi: 10.1097/IGC.0000000000000264. Review.

PMID:
25341586
15.

Five-year outcomes of adjuvant carboplatin/paclitaxel chemotherapy and intravaginal radiation for stage I-II papillary serous endometrial cancer.

Kiess AP, Damast S, Makker V, Kollmeier MA, Gardner GJ, Aghajanian C, Abu-Rustum NR, Barakat RR, Alektiar KM.

Gynecol Oncol. 2012 Nov;127(2):321-5. doi: 10.1016/j.ygyno.2012.07.112. Epub 2012 Jul 28.

PMID:
22850412
16.

Optimal surgical debulking in uterine papillary serous carcinoma affects survival.

Patsavas K, Woessner J, Gielda B, Rotmensch J, Yordan E, Bitterman P, Guirguis A.

Gynecol Oncol. 2011 Jun 1;121(3):581-5. doi: 10.1016/j.ygyno.2010.11.048. Epub 2011 Mar 25.

PMID:
21440290
17.

Uterine papillary serous carcinoma: epidemiology, pathogenesis and management.

Fader AN, Boruta D, Olawaiye AB, Gehrig PA.

Curr Opin Obstet Gynecol. 2010 Feb;22(1):21-9. doi: 10.1097/GCO.0b013e328334d8a3. Review.

PMID:
19952744
19.

Human kallikrein 6: a new potential serum biomarker for uterine serous papillary cancer.

Santin AD, Diamandis EP, Bellone S, Soosaipillai A, Cane S, Palmieri M, Burnett A, Roman JJ, Pecorelli S.

Clin Cancer Res. 2005 May 1;11(9):3320-5.

20.

Comparative outcomes assessment of uterine grade 3 endometrioid, serous, and clear cell carcinomas.

Ayeni TA, Bakkum-Gamez JN, Mariani A, McGree ME, Weaver AL, Haddock MG, Keeney GL, Long HJ 3rd, Dowdy SC, Podratz KC.

Gynecol Oncol. 2013 Jun;129(3):478-85. doi: 10.1016/j.ygyno.2013.03.011. Epub 2013 Mar 25.

PMID:
23535279

Supplemental Content

Support Center